CU20220049A7 - Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden - Google Patents
Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprendenInfo
- Publication number
- CU20220049A7 CU20220049A7 CU2022000049A CU20220049A CU20220049A7 CU 20220049 A7 CU20220049 A7 CU 20220049A7 CU 2022000049 A CU2022000049 A CU 2022000049A CU 20220049 A CU20220049 A CU 20220049A CU 20220049 A7 CU20220049 A7 CU 20220049A7
- Authority
- CU
- Cuba
- Prior art keywords
- quinazolin
- methoxyphenyl
- trifluoromethyl
- fluoro
- methoxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p><br /> La presente invención se refiere a una forma cristalina de trihidrato de sodio del ácido<br /> 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4<em>H</em>-quinazolin-4-il]acético de formula I</p> <p>ESPACIO PARA FÓRMULA</p> <p>a un método eficaz para su preparación, así como a composiciones farmacéuticas que comprende a dicho compuesto.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20159727 | 2020-02-27 | ||
| PCT/EP2021/055045 WO2021170874A1 (en) | 2020-02-27 | 2021-03-01 | A method of producing a crystalline form of sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate trihydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20220049A7 true CU20220049A7 (es) | 2023-04-10 |
| CU24749B1 CU24749B1 (es) | 2025-05-05 |
Family
ID=69742722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2022000049A CU24749B1 (es) | 2020-02-27 | 2021-03-01 | Método para preparar una forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil) fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230219899A1 (es) |
| EP (1) | EP4110470A1 (es) |
| JP (2) | JP7645276B2 (es) |
| KR (1) | KR102889550B1 (es) |
| CN (1) | CN115581118B (es) |
| AR (1) | AR121439A1 (es) |
| AU (1) | AU2021225363B2 (es) |
| BR (1) | BR112022016929A2 (es) |
| CA (1) | CA3169484A1 (es) |
| CL (1) | CL2022002291A1 (es) |
| CO (1) | CO2022012039A2 (es) |
| CU (1) | CU24749B1 (es) |
| EC (1) | ECSP22066680A (es) |
| IL (1) | IL295795A (es) |
| MX (1) | MX2022010441A (es) |
| PE (1) | PE20230515A1 (es) |
| PH (1) | PH12022552260A1 (es) |
| PY (1) | PY2116983A (es) |
| TW (1) | TWI870559B (es) |
| UA (1) | UA128999C2 (es) |
| UY (1) | UY39096A (es) |
| WO (1) | WO2021170874A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PY24113872A (es) | 2023-12-21 | 2025-07-29 | Aic 246 Ag & Co Kg | Sales diastereoméricas de aminoalchohol y aminoéter de ácido 2-[(4r,s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il]acético y su uso para separación enantiomérica.- |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
-
2021
- 2021-02-26 UY UY0001039096A patent/UY39096A/es unknown
- 2021-02-26 AR ARP210100497A patent/AR121439A1/es unknown
- 2021-02-26 PY PY202102116983A patent/PY2116983A/es unknown
- 2021-03-01 EP EP21708227.0A patent/EP4110470A1/en active Pending
- 2021-03-01 WO PCT/EP2021/055045 patent/WO2021170874A1/en not_active Ceased
- 2021-03-01 CA CA3169484A patent/CA3169484A1/en active Pending
- 2021-03-01 PH PH1/2022/552260A patent/PH12022552260A1/en unknown
- 2021-03-01 UA UAA202203502A patent/UA128999C2/uk unknown
- 2021-03-01 IL IL295795A patent/IL295795A/en unknown
- 2021-03-01 PE PE2022001822A patent/PE20230515A1/es unknown
- 2021-03-01 BR BR112022016929A patent/BR112022016929A2/pt unknown
- 2021-03-01 AU AU2021225363A patent/AU2021225363B2/en active Active
- 2021-03-01 JP JP2022551816A patent/JP7645276B2/ja active Active
- 2021-03-01 MX MX2022010441A patent/MX2022010441A/es unknown
- 2021-03-01 CU CU2022000049A patent/CU24749B1/es unknown
- 2021-03-01 US US17/802,792 patent/US20230219899A1/en active Pending
- 2021-03-01 KR KR1020227033588A patent/KR102889550B1/ko active Active
- 2021-03-01 CN CN202180016769.0A patent/CN115581118B/zh active Active
- 2021-03-02 TW TW110107368A patent/TWI870559B/zh active
-
2022
- 2022-08-22 CL CL2022002291A patent/CL2022002291A1/es unknown
- 2022-08-24 EC ECSENADI202266680A patent/ECSP22066680A/es unknown
- 2022-08-24 CO CONC2022/0012039A patent/CO2022012039A2/es unknown
-
2024
- 2024-10-23 JP JP2024186290A patent/JP2025016547A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ792583A (en) | 2025-07-25 |
| CU24749B1 (es) | 2025-05-05 |
| PY2116983A (es) | 2022-04-18 |
| AU2021225363A1 (en) | 2022-10-13 |
| JP2025016547A (ja) | 2025-02-04 |
| UY39096A (es) | 2021-09-30 |
| JP2023519813A (ja) | 2023-05-15 |
| CO2022012039A2 (es) | 2022-11-18 |
| UA128999C2 (uk) | 2024-12-18 |
| PE20230515A1 (es) | 2023-03-24 |
| CN115581118A (zh) | 2023-01-06 |
| CA3169484A1 (en) | 2021-09-02 |
| BR112022016929A2 (pt) | 2022-12-06 |
| EP4110470A1 (en) | 2023-01-04 |
| TW202140453A (zh) | 2021-11-01 |
| KR20220148863A (ko) | 2022-11-07 |
| WO2021170874A1 (en) | 2021-09-02 |
| US20230219899A1 (en) | 2023-07-13 |
| JP7645276B2 (ja) | 2025-03-13 |
| MX2022010441A (es) | 2022-10-18 |
| AU2021225363B2 (en) | 2024-09-19 |
| CL2022002291A1 (es) | 2023-02-03 |
| PH12022552260A1 (en) | 2023-11-13 |
| TWI870559B (zh) | 2025-01-21 |
| KR102889550B1 (ko) | 2025-11-24 |
| IL295795A (en) | 2022-10-01 |
| ECSP22066680A (es) | 2022-12-30 |
| CN115581118B (zh) | 2025-01-28 |
| AR121439A1 (es) | 2022-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2397976C2 (ru) | Производные бензамидов и гетероаренов | |
| MX2021003460A (es) | Fabricacion de compuestos y composiciones para inhibir la actividad de shp2. | |
| PE20091099A1 (es) | Derivados de aminobenzamida como agentes utiles para controlar parasitos animales | |
| AR084639A1 (es) | Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo | |
| UY37399A (es) | Proceso químico para la elaboración de determinados derivados de pirimidina | |
| CU24316B1 (es) | Nuevos derivados fosfatos de 1,2,3,4-tetraisoquinolina amida fenilo, métodos de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| CL2012001841A1 (es) | Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. | |
| EA201001772A1 (ru) | Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей | |
| PE20160899A1 (es) | Derivados de acido heteroaril butanoico como inhibidores de lta4h | |
| HK1219222A1 (zh) | 包含降血脂药的制剂 | |
| CL2024000756A1 (es) | Sal de potasio de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético | |
| EA201390481A1 (ru) | Кристаллические оксалатные соли диамидного соединения | |
| PE20141201A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) | |
| CU20220049A7 (es) | Forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato, método para su preparación y composiciones farmacéuticas que la comprenden | |
| NZ593048A (en) | Composition for controlling plant diseases comprising an alkoxyphenylacetic acid compound and at least one compound selected from tolclofos-methyl, metalaxyl and mefenoxam | |
| EA201270653A1 (ru) | Антагонист dpи его применение | |
| BRPI0608400B8 (pt) | composto 2-(((4-((2,2-dimetil-1,3-dioxan-5-il)metóxi)-3,5-dimetilpiridin-2-il)metil)sulfinil)-1h-benzimidazol ou um sal de metal alcalino do mesmo | |
| ECSP22066666A (es) | Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3- metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]- 4h-quinazolin-4-il]acético | |
| ECSP22066670A (es) | 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso | |
| RU2009147291A (ru) | Применение ингибиторов raf для лечения рака щитовидной железы | |
| NO20084326L (no) | Fremgangsmate for fremstilling av [(1R), 2S]-2-aminopropansyre 2-[4-(4-fluor-2-metyl-1H-indol-5-yloksy)-5-metylpyrrolo[2,1-f][1,2,4]triazin-6-yloksy]-1-metyletylester | |
| EA201101175A1 (ru) | Фармацевтические комбинации 5-фторурацила и производных 1,4-дигидропиридина и их применение для лечения рака | |
| EA201000119A1 (ru) | Фармацевтические композиции, содержащие монохолиновые соли янтарной кислоты | |
| AR071256A1 (es) | Ciclopropancarboxilato, su uso, metodo de preparacion de dicho compuesto y metodo de control de plagas | |
| PE20160890A1 (es) | Inhibidor de beta-lactamasa cristalina |